NO122568B - - Google Patents

Download PDF

Info

Publication number: NO122568B
Authority: NO; Norway
Prior art keywords: adrenocorticotropin; preparation; solution; gelatin; added
Prior art date: 1966-04-04

Application number

NO16244666A

Other languages

English (en)

Norwegian (no)

Inventor

A Rudaz

Original Assignee

Secheron Atel

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1966-04-04

Filing date

1966-04-04

Publication date

1971-07-12

1966-04-04 Application filed by Secheron Atel filed Critical Secheron Atel

1966-04-04 Priority to NO16244666A priority Critical patent/NO122568B/no

1971-07-12 Publication of NO122568B publication Critical patent/NO122568B/no

Links

229960000258 corticotropin Drugs 0.000 claims description 58
101800000414 Corticotropin Proteins 0.000 claims description 57
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims description 56
238000002360 preparation method Methods 0.000 claims description 47
229920000159 gelatin Polymers 0.000 claims description 16
239000008273 gelatin Substances 0.000 claims description 16
238000000034 method Methods 0.000 claims description 15
239000003638 chemical reducing agent Substances 0.000 claims description 14
108010010803 Gelatin Proteins 0.000 claims description 12
235000019322 gelatine Nutrition 0.000 claims description 12
235000011852 gelatine desserts Nutrition 0.000 claims description 12
239000007864 aqueous solution Substances 0.000 claims description 8
125000003396 thiol group Chemical group [H]S* 0.000 claims description 7
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 5
235000018417 cysteine Nutrition 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
239000000243 solution Substances 0.000 description 24
239000007788 liquid Substances 0.000 description 12
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
230000003023 adrenocorticotropic effect Effects 0.000 description 8
238000002347 injection Methods 0.000 description 8
239000007924 injection Substances 0.000 description 8
238000003860 storage Methods 0.000 description 7
229960002433 cysteine Drugs 0.000 description 6
230000000694 effects Effects 0.000 description 5
239000011521 glass Substances 0.000 description 5
239000000047 product Substances 0.000 description 5
229960001305 cysteine hydrochloride Drugs 0.000 description 4
230000001817 pituitary effect Effects 0.000 description 4
CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 4
230000002378 acidificating effect Effects 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
239000000284 extract Substances 0.000 description 3
238000010438 heat treatment Methods 0.000 description 3
230000007935 neutral effect Effects 0.000 description 3
239000001488 sodium phosphate Substances 0.000 description 3
230000006641 stabilisation Effects 0.000 description 3
238000011105 stabilization Methods 0.000 description 3
238000010254 subcutaneous injection Methods 0.000 description 3
239000007929 subcutaneous injection Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
229910000406 trisodium phosphate Inorganic materials 0.000 description 3
235000019801 trisodium phosphate Nutrition 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
239000003513 alkali Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
230000000087 stabilizing effect Effects 0.000 description 2
239000007858 starting material Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
-1 zinc acetate Chemical class 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
206010062767 Hypophysitis Diseases 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
241001494479 Pecora Species 0.000 description 1
241000700159 Rattus Species 0.000 description 1
241000282887 Suidae Species 0.000 description 1
ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
210000004404 adrenal cortex Anatomy 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
239000002156 adsorbate Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000012043 crude product Substances 0.000 description 1
238000003795 desorption Methods 0.000 description 1
230000001687 destabilization Effects 0.000 description 1
230000029142 excretion Effects 0.000 description 1
230000009931 harmful effect Effects 0.000 description 1
230000035876 healing Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
244000144972 livestock Species 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000000203 mixture Substances 0.000 description 1
231100000344 non-irritating Toxicity 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
238000010979 pH adjustment Methods 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
210000003635 pituitary gland Anatomy 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000012264 purified product Substances 0.000 description 1
238000010791 quenching Methods 0.000 description 1
230000000171 quenching effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000000126 substance Substances 0.000 description 1
PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
238000005406 washing Methods 0.000 description 1
150000003751 zinc Chemical class 0.000 description 1
239000004246 zinc acetate Substances 0.000 description 1

Landscapes

Medicinal Preparation (AREA)

NO16244666A 1966-04-04 1966-04-04 NO122568B (da)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
NO16244666A NO122568B (da)	1966-04-04	1966-04-04

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
NO16244666A NO122568B (da)	1966-04-04	1966-04-04

Publications (1)

Publication Number	Publication Date
NO122568B true NO122568B (da)	1971-07-12

Family

ID=19909509

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO16244666A NO122568B (da)	1966-04-04	1966-04-04

Country Status (1)

Country	Link
NO (1)	NO122568B (da)

1966
- 1966-04-04 NO NO16244666A patent/NO122568B/no unknown

Publication	Publication Date	Title
Thorn et al.	1937	The" sodium retaining effect" of the sex hormones
JP5522877B2 (ja)	2014-06-18	モキシフロキサシン／塩化ナトリウム製剤
NO161204B (no)	1989-04-10	Fremgangsmaate for fremstilling av en insulinopploesning.
EP0176094A1 (en)	1986-04-02	Parenteral alimentation solution
KR20130080422A (ko)	2013-07-12	엔로플록사신의 주사제 및 그의 제조방법
KR102054942B1 (ko)	2019-12-11	남성 불임을 치료하기 위한 ｄ－아스파르트산 및 ｌ－아스파르트산 또는 이들 염의 조합체의 용도
NO20061458L (no)	2006-07-03	Infusjonspreparat inneholdende (2R)-2-propyloktansyre som den aktive bestanddel
Zarrow et al.	1951	Mechanism of adrenal involution in the rat after treatment with thiouracil
Gona et al.	1974	Failure of synthetic TRF to elicit metamorphosis in frog tadpoles or red-spotted newts
US3152955A (en)	1964-10-13	Amino acids concentrate
NO122568B (da)	1971-07-12
RU2437653C1 (ru)	2011-12-27	Способ лечения и профилактики желудочно-кишечных болезней новорожденных телят
JP6950966B2 (ja)	2021-10-13	スガマデクス又はその薬理学的に許容される塩含有液剤及びその製造方法
DE2455203C2 (da)	1987-07-23
CN110664738A (zh)	2020-01-10	一种葡萄糖酸钙口服溶液及其制备方法
US4259353A (en)	1981-03-31	Infusion solutions for the treatment of hepatic encephalopathy and method of using them
RU2363483C1 (ru)	2009-08-10	Способ профилактики вторичных иммунодефицитов у молодняка крупного рогатого скота
DE2404265A1 (de)	1975-07-31	Verfahren zur gewinnung von immunglobulinen
JP2720165B2 (ja)	1998-02-25	ぶどう糖電解質配合剤
GB2194885A (en)	1988-03-23	Pharmaceutical compositions containing vanadium
JPS60260510A (ja)	1985-12-23	ケトン症治療用の注射溶液
US2192386A (en)	1940-03-05	Insulin preparation and process
US2521793A (en)	1950-09-12	Removal of pyrogens from amino acid solutions
JPH0414646B2 (da)	1992-03-13
RU2320352C2 (ru)	2008-03-27	Способ лечения субклинического мастита у коров